Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer

被引：1

作者：

Mouri, Atsuto ^{[1
]}

Kaira, Kyoichi ^{[1
]}

Yamaguchi, Ou ^{[1
]}

Hashimoto, Kosuke ^{[1
]}

Miura, Yu ^{[1
]}

Shiono, Ayako ^{[1
]}

Kawasaki, Tomonori ^{[2
]}

Kobayashi, Kunihiko ^{[1
]}

Imai, Hisao ^{[1
]}

Kagamu, Hiroshi ^{[1
]}

机构：

[1] Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan

[2] Saitama Med Univ, Int Med Ctr, Dept Pathol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 29卷 / 02期

基金：

日本学术振兴会;

关键词：

Antinuclear antibody; PD-L1; Non-small cell lung cancer; Pembrolizumab; T-CELL; IMMUNOTHERAPY; CHEMOTHERAPY; EFFICACY; DISEASE; IMPACT;

D O I：

10.1007/s10147-023-02445-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundThe relationship between antinuclear antibody (ANA) and the efficacy of programmed death-1 (PD-1) blockade remains controversial. Here, we investigated the prognostic significance of ANA titer in patients with non-small cell lung cancer (NSCLC) receiving pembrolizumab monotherapy as the first-line treatment, compared with that of platinum-based chemotherapy with PD-1 blockade.MethodsOur clinical data based on the ANA titer (1:80) were retrospectively reviewed for patients with advanced NSCLC, who were treated with first-line pembrolizumab monotherapy and platinum-based chemotherapy with PD-1 blockade. Immunohistochemical staining for tumor-infiltrating lymphocytes such as CD4, CD8 and Foxp3 was performed.ResultsAmong 106 patients treated with pembrolizumab, 19 (17.9%) tested high for ANA. Progression-free survival (PFS) and overall survival (OS) were significantly better in patients with high ANA than in those with low ANA, and high ANA was identified as an independent prognostic predictor, particularly in the subgroup with programmed death ligand-1 (PD-L1) >= 50%. However, no statistically significant difference in PFS and OS based on the ANA titer was observed in 59 patients treated with combinational chemotherapy and immunotherapy. High numbers of intratumoral Foxp3 and stromal CD8 were significantly associated with low ANA.ConclusionsAssessment of preexisting ANA titers was useful to prognose PD-1 blockade as a first-line setting, particularly for the PD-L1 >= 50% subgroup, but not in the case of combined immunotherapy and chemotherapy.

引用

页码：124 / 133

页数：10

共 21 条

[21] Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies
Yoneshima, Yasuto
Tanaka, Kentaro
Shiraishi, Yoshimasa
Hata, Kojiro
Watanabe, Hiroyuki
Harada, Taishi
Otsubo, Kohei
Iwama, Eiji
Inoue, Hiroyuki
Masuda, Satohiro
Nakanishi, Yoichi
Okamoto, Isamu
[J]. LUNG CANCER, 2019, 130 : 5 - 9

← 1 2 3 →